A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

NCT ID: NCT06083623

Last Updated: 2023-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

2250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-06

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), neutralizing antibody and antidrug antibody (ADA) response for TNM001 in infants entering their first RSV season.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study adopts an adaptive seamless dose selection design and consists of two parts: Part 1 is a phase 2b dose ranging trial which will support to determine the dose for Part 2, the phase 3 trial. The study population includes early and mid-term preterm infants \[gestational age (GA)﹤35 weeks 0 day\] and late preterm infants or full-term infants (≥35 weeks 0 day GA), with or without Congenital Heart Disease (CHD) or premature infants Chronic Lung Disease (CLD). A total of approximately 2250 infants will be randomized 2:1 to receive either TNM001 or placebo. All subjects will be followed for 240 days after dosing. This study will be conducted in appropriately 50 sites in China.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Syncytial Virus Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TNM001

Group Type EXPERIMENTAL

TNM001

Intervention Type BIOLOGICAL

single dose intramuscular injection

Placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type BIOLOGICAL

single dose intramuscular injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TNM001

single dose intramuscular injection

Intervention Type BIOLOGICAL

placebo

single dose intramuscular injection

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Early and mid-term preterm infants (\<35 weeks 0 day GA) and late preterm infants or full-term infants (≥35 weeks 0 day GA) under 1 year of age, with or without Congenital Heart Disease (CHD) or premature infants Chronic Lung Disease (CLD),who are entering their first RSV season at the time of screening.

Exclusion Criteria

* 1\. Any fever (\> 38.0°C) or acute illness within 7 days prior to randomization
* 2\. History of RSV infection or active RSV infection prior to, or at the time of, randomization
* 3\. Drug medication prior to randomization or expected to be treated by medicines during the study period.
* 4\. Currently receiving or expected to receive immunosuppressive therapy during the study period.
* 5\. Renal impairment or hepatic dysfunction
* 6\. Nervous system disease or neuromuscular disease
* 7\. Prior history of a suspected or actual acute life-threatening event
* 8\. Known immunodeficiency including HIV, mother with HIV infection unless the child's infection has been excluded.
* 9\. Known allergy history of immunoglobulin products, receipt or expected to receive immunoglobulins or blood products during the study period.
* 10.Receipt of RSV vaccine or mAb
Minimum Eligible Age

0 Years

Maximum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhuhai Trinomab Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hanmin Liu, MD

Role: PRINCIPAL_INVESTIGATOR

West China Second Hospital, Sichuan University

Enmei Liu, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital of Chongqing Medical University

Ying Wang

Role: STUDY_DIRECTOR

Zhuhai Trinomab Pharmaceutical Co., Ltd.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University Third Hospital

Beijing, Beijing Municipality, China

Site Status

Children's Hospital Capital Institute Pediatrics

Beijing, Beijing Municipality, China

Site Status

Jiangjin Central Hospital

Chongqing, Chongqing Municipality, China

Site Status

Xiamen maternal and Child Health Hospital

Xiamen, Fujian, China

Site Status

The Third Affiliated Hospital of Guangzhou Medical University

Guangdong, Guangdong, China

Site Status

Guangdong Maternal and Child Health Care Hospital

Guangzhou, Guangdong, China

Site Status

University of Chinese Academy of Sciense Shenzhen Hospital

Shenzhen, Guangdong, China

Site Status

Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China

Site Status

LiuZhou People's Hospital

Liuzhou, Guangxi, China

Site Status

Maternity and Child Health Care of Guangxi Zhuang Autonomous Region

Nanning, Guangxi, China

Site Status

HaiNan Women and Children's Medical Center

Haikou, Hainan, China

Site Status

Hebei Petro China Central Hospital

Langfang, Hebei, China

Site Status

The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Site Status

The Second Hospital of HeBei Medical University (HBMU)

Shijiazhuang, Hebei, China

Site Status

Tangshan Maternal and Child Health Hospitaltangshan Maternal and Child Health Hospital

Tangshan, Hebei, China

Site Status

Sanmenxia Central Hospital

Sanmenxia, Henan, China

Site Status

Xinxiang First People's Hospital

Xinxiang, Henan, China

Site Status

Henan (Zhengzhou) Children's Hospital

Zhengzhou, Henan, China

Site Status

Renmin Hospital of Wuhan University

Wuhan, Hubei, China

Site Status

The Central Hospital of Wuhan

Wuhan, Hubei, China

Site Status

The First People'S Hospital of Changde City

Changde, Hunan, China

Site Status

The Maternal and Child Health Hospital of Hunan Province

Changsha, Hunan, China

Site Status

Xiangya Hospital Central South University

Changsha, Hunan, China

Site Status

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

Site Status

The Second Hospital University of South China

Hengyang, Hunan, China

Site Status

Loudi Central Hospital

Loudi, Hunan, China

Site Status

The First Affiliated Hospital of Shaoyang University

Shaoyang, Hunan, China

Site Status

Jiangxi Maternal and Child Health Hospital

Nanchang, Jiangxi, China

Site Status

Children's Hospital Affiliated to Shandong University

Jinan, Shandong, China

Site Status

The affiliated children'shospital fudan university

Shanghai, Shanghai Municipality, China

Site Status

Linfen Central Hospital

Linfen, Shanxi, China

Site Status

Linfen People's Hospital

Linfen, Shanxi, China

Site Status

Yuncheng Central Hospital

Yuncheng, Shanxi, China

Site Status

Chengdu Women's and Children's Central Hospital

Chengdu, Sichuan, China

Site Status

West China Second University Hospital, Sichuan University

Chengdu, Sichuan, China

Site Status

Children's Hospital of Chongqing Medical University

Chongqing, Sichuan, China

Site Status

Mianyang Peoples Hospital

Mianyang, Sichuan, China

Site Status

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine/Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

Site Status

Ningbo Women&Children's Hospital

Ningbo, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ying Wang

Role: CONTACT

+86 0756 7263999

Shiru Zhao

Role: CONTACT

+86 0756 7263999

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tongyan Han

Role: primary

+86 13520695016

Ling Cao

Role: primary

+86 13910610319

Hong Fu

Role: primary

+86 15123226406

Tong Shen

Role: primary

+86 13950155429

Fan Wu

Role: primary

+86 18127862115

Jieling Wu

Role: primary

+86 13600456180

Wenhui Zhang

Role: primary

+86 137 9826 5975

Juan Peng

Role: primary

+86 15907738875

Xingjiang Long

Role: primary

+86 13627725688

Jielin Chen

Role: primary

+86 13517666951

Wei Xiang

Role: primary

+86 18608981299

Xinjian Liu

Role: primary

+86 13930601503

Lian Jiang

Role: primary

+86 13831117651

Zhiqing Zhang

Role: primary

+86 15803210627

Xiaoning Wang

Role: backup

+86 13833118294

Yuying Wang

Role: primary

+86 13932537139

Chunying Ma

Role: primary

+86 15978336266

Chunhui Zhang

Role: primary

+86 15670505357

Xiuhong Jin

Role: primary

+86 13525552263

Baozhen Yao

Role: primary

+86 13986147892

Hong Jiang

Role: primary

+86 15927526319

Minghui Wang

Role: primary

+86 13607367063

Xiangfeng Yang

Role: primary

13875962130

Xiangrong Zheng

Role: primary

+86 13508484326

Minghua Yang

Role: primary

+86 13973135843

Qingpeng Hu

Role: primary

+86 13357248086

Yiran Liu

Role: primary

+86 13973837171

Xinping Peng

Role: primary

+86 13975951076

Qingxiong Zhu

Role: primary

+86 15979003000

Yuling Han

Role: primary

+86 13969098010

Libo Wang

Role: primary

+86 18017590801

Jiangli Xi

Role: primary

+86 13753758090

Jiangchuan Zhu

Role: primary

+86 13303576606

Lihe Wang

Role: primary

+86 15503599191

Fengli Zhao

Role: backup

+86 18235960066

Yulei Yu

Role: primary

+86 15388101587

Hanmin Liu

Role: primary

+86 18180609009

Qin Qin

Role: backup

+86 18180603576

EnMei Liu, MD

Role: primary

13368070773

Yan Li

Role: primary

+86 13890190821

Chunming Jiang

Role: primary

+86 13606610578

Hehe Chen

Role: primary

+86 13605883884

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTR20232792

Identifier Type: OTHER

Identifier Source: secondary_id

TNM001-301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MVA-BN-RSV Vaccine Trial
NCT05238025 TERMINATED PHASE3